Safe delivery of a highly toxic anthracycline derivative through liposomal nanoformulation achieves complete cancer regression.

ABSTRACT:

Background

Chemotherapy remains the cornerstone of cancer treatment despite its well-documented challenges, including toxic side effects and drug resistance. Here, we demonstrate that a novel, highly toxic, daunosamine-modified derivative of daunorubicin (2-pyrrolino-daunorubicin, PyDau) can be safely administered to mice when encapsulated in liposome.

Methods

PyDau was synthesized from daunorubicin in a one-step reaction. Its increased in vitro cytotoxicity was confirmed across 42 human cell lines representing 12 cancer types, including multidrug resistant cells. The activity profile of this new derivative was analyzed in the context of 13 commonly used cancer drugs across a panel of lymphoblast cell lines missing individual components of DNA-repair enzymes. To enable in vi

SUBMITTER: Furedi A 

PROVIDER: S-EPMC12557964 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature